Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,029 people get NAVB articles and Market Currents by email alert.
Get email alerts on NAVB »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Business Wire (May 29, 2013)
-
Business Wire (May 15, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 5, 2013)
-
Business Wire (Apr 3, 2013)
-
Business Wire (Apr 1, 2013)
NAVB vs. ETF Alternatives
Company Description
Currently, there's no company description for NAVB.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Wednesday, May 1, 9:10 AM
Premarket gainers: IQNT +34%. MSPD +31%. TRLA +14%. FIRE +12%. JRCC +11%. CAAS +8%. DWA +9%. GDOT +8%. CAVM +8%. NAVB +5%.
Losers: HIMX -9%. ELGX -8%. SWI -8%. Comment! [On the Move] - Thursday, April 18, 2:12 PM Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia demonstrated imaging characteristics nearly identical to those of an acknowledged benchmark, gold-standard amyloid imaging agent, 11C-labeled Pittsburgh Compound-B. The authors believe these results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer’s disease. Comment! [Healthcare, On the Move]
-
Wednesday, April 17, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: CONE +9%. SLCA +4%. MXIM +4%. LNC +4%. MHR +3%.
After-hours top losers: SCSS -7%. CCK -4%. SNDK -3%. NAVB -3%. EBAY -2%. Comment! [On the Move] -
Tuesday, April 9, 5:56 PM
After-hours top gainers, as of 5:15 p.m.: ACTS +8%. PSUN +6%. PZE +5%. PSMT +4%. NAVB +3%.
After-hours top losers: SGYP -12%. HMA -11%. SEAC -10%. RLGY -7%. THC -5%. Comment! [On the Move] -
Thursday, April 4, 9:10 AM
Premarket gainers: CBMX +20%. PSDV +13%. NAVB +10%. ALU +9%. ARIA +6%.
Comment! [On the Move] - Thursday, April 4, 8:20 AM Navidea Biopharmaceuticals (NAVB +7.8%) after saying that its Lymphoseek radiopharmaceutical met its primary endpoint in a Phase III trial by identifying sentinel lymph nodes in patients with squamous cell carcinoma (skin cancer) of the head or in the mouth, Until now, expensive surgery has been used. Following the results, the study's Data Safety Monitoring Committee has recommended that Navidea close the trial early. (PR) Comment! [Healthcare, On the Move]
- Wednesday, March 27, 12:04 PM Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment in Phase 2b positron emission tomography imaging studies of NAV4694, a scan for detecting cerebral-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment. The study is designed to investigate whether scan findings have the ability to distinguish between subjects with MCI who progress to Alzheimer's disease from those who do not. 1 Comment [Healthcare, On the Move]
- Wednesday, March 13, 1:44 PM The FDA has approved Navidea Biopharmaceutical's (NAVB -7.4%) Lymphoseek injection, a radioactive imaging agent meant to help doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove the lymph nodes. The drug, which is the first new lymph-node mapping agent approved in more than 30 years, is injected into the tumor area and later, using a hand-held radiation detector, identifies lymph nodes that have taken up Lymphoseek. 8 Comments [Healthcare, On the Move]
-
Tuesday, March 5, 6:07 PM
After-hours top gainers, as of 5:30 p.m.: HCI +11%. ELX +10%. HNR +8%. PAY +5%. BPZ +4%.
After-hours top losers: AVAV -22%. HLS -11%. NAVB -7%. JMBA -6%. IMUC -5%. Comment! [On the Move] - Wednesday, January 30, 11:35 AM Navidea Biopharmaceuticals (NAVB +3.2%) moves up today after pricing its 1.54M shares secondary offering at $3.10 per share, just a penny shy of yesterday's close. The gross proceeds of sale total approximately $4.8M, and the company plans to use the proceeds to fund it's ongoing operations. Comment! [Healthcare, On the Move]
- Tuesday, January 22, 12:32 PM Navidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the shares with a Market Outperform on valuation and a price target of $5 a share. The firm says the stock represents an undervalued opportunity with multiple near-term drivers that are likely to create shareholder value in 2013. Separately, Aegis Capital starts the stock with a Hold rating and a $3.00 price target. 1 Comment [Healthcare, On the Move]
-
Thursday, January 3, 5:42 PM
After-hours top gainers, as of 5:15 p.m.: NAVB +5%. ROVI +5%. SHLM +5%. UVXY +2%. SNTS +2%.
After-hours top losers: ARAY -20%. VTNC -7%. SUSP -6%. ITMN -6%. FUN -5%. Comment! [On the Move] -
Wednesday, January 2, 5:37 PM
After-hours top gainers, as of 5:15 p.m.: BGMD +14%. KYAK +8%. SZYM +6%. LNDC +4%. NAVB +3%.
After-hours top losers: MLNX -16%. RMBS -12%. ESIO -8%. AUO -6%. OME -4%. 1 Comment [On the Move] -
Tuesday, November 20, 2012, 5:39 PM
After-hours top gainers, as of 5:15 p.m.: MEMS +83.3%. NAVB +9.7%. VELT +6.9%. XOMA +6.3%. ANFI +6.0%.
After-hours top losers: TLYS -16.9%. ZLC -12.6%. DNDN -3.4%. MBI -2.2%. CHTR -2.1%. Comment! [On the Move] - Wednesday, November 14, 2012, 10:56 AM Navidea Biopharmaceuticals (NAVB -4.3%) slips on disappointment that the FDA is giving a six month window to approve Lymphoseek, its Lymphoma diagnostic tool, rather than the two-month review time-frame some investors were betting on. The agency had rejected NAVB's first application in September, citing problems caused by its third-party manufacturer, and it now has to re-inspect the manufacturing site before deciding on the drug. 2 Comments [Healthcare, On the Move]
-
Tuesday, October 9, 2012, 9:10 AM
Premarket gainers: RSH +11%. EMXX +10%. QCOR +7%. NAVB +6%.
Losers: EW -17%. ATHX -14%. OC -7%. NFLX -7%. ALU -5%. 3 Comments [On the Move]
-
- View all 0 replies
-
- View all 1 replies
-
-
oneotherfool
$NAVB CEO to provide an update of the Company and its development programs April 5 at the Future Leaders in the Biotech Industry Conference - View all 0 replies
-
oneotherfool
$NAVB Price as of Thursday close 3/28/13 is $2.71 according to Nasdaq. The displayed value of $2.66 is wrong, or am I missing something? - View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 15 replies
-
-
LEIGHDIST: im still in amrn also waiting for nce this week hopefully, have you heard anything
-
- View all 0 replies
-
John McCoy
$NAVB up 10% this week, closing today at $3.29. Looks to be starting it's run up to PDUFA date. - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
oneotherfool
$NAVB Price as of Thursday close 3/28/13 is $2.71 according to Nasdaq. The displayed value of $2.66 is wrong, or am I missing something? - View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 15 replies
-
-
LEIGHDIST: im still in amrn also waiting for nce this week hopefully, have you heard anything
-
- View all 12 replies
-
-
-
Scott Matusow
$NAVB fail, those who listen to my show on a reg basis know I have never liked management there. - View all 3 replies
-
thsearfoss: With that said, do you see a potential opportunity if they figure this road block out?
-
-
- View all 2 replies
-
reachmygoals1: large blocks of buys friday sept 7, lets see if this continues into monday or halt for fda decision. good luck to all holding NAVB
-
-
- View all 7 replies
-
Manuel Pastore: Stock will rally all of next week prior to the PDUFA date, now is a great entry before the run! -
Manuel Pastore: If approved, is definitely breaking into new, never seen highs! for the company of course.
-
- View all 1 replies
-